Roth Capital Issues Positive Estimate for CLRB Earnings

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Equities researchers at Roth Capital boosted their Q2 2025 earnings estimates for shares of Cellectar Biosciences in a note issued to investors on Wednesday, June 11th. Roth Capital analyst J. Aschoff now anticipates that the biopharmaceutical company will post earnings per share of ($0.12) for the quarter, up from their previous estimate of ($0.13). The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.59) per share. Roth Capital also issued estimates for Cellectar Biosciences’ Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.47) EPS, FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.39) EPS, FY2028 earnings at ($0.04) EPS and FY2029 earnings at $0.20 EPS.

Cellectar Biosciences (NASDAQ:CLRB) last announced its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04.

Other equities research analysts have also issued research reports about the stock. Maxim Group reissued a “hold” rating on shares of Cellectar Biosciences in a research report on Wednesday, May 14th. Wall Street Zen began coverage on shares of Cellectar Biosciences in a research report on Wednesday, May 21st. They issued a “sell” rating for the company.

Cellectar Biosciences Stock Performance

Shares of CLRB stock opened at $0.41 on Monday. Cellectar Biosciences has a one year low of $0.22 and a one year high of $3.23. The company has a 50 day moving average price of $0.29 and a 200 day moving average price of $0.36. The firm has a market capitalization of $19.04 million, a price-to-earnings ratio of -0.24 and a beta of 0.52.

Institutional Investors Weigh In On Cellectar Biosciences

A number of large investors have recently added to or reduced their stakes in CLRB. Squarepoint Ops LLC acquired a new stake in Cellectar Biosciences during the 4th quarter valued at $156,000. Sequoia Financial Advisors LLC grew its holdings in Cellectar Biosciences by 1,301.8% during the 1st quarter. Sequoia Financial Advisors LLC now owns 203,260 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 188,760 shares in the last quarter. Baader Bank Aktiengesellschaft acquired a new stake in Cellectar Biosciences during the 1st quarter valued at $55,000. JPMorgan Chase & Co. boosted its stake in Cellectar Biosciences by 687.3% during the 4th quarter. JPMorgan Chase & Co. now owns 182,403 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 159,234 shares during the last quarter. Finally, Simplex Trading LLC boosted its stake in Cellectar Biosciences by 331.3% during the 1st quarter. Simplex Trading LLC now owns 173,129 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 132,986 shares during the last quarter. 16.41% of the stock is owned by institutional investors and hedge funds.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.